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The goal of this thesis was to optimize moxifloxacin (MFX) treatment for tuberculosis (TB) 
patients. We therefore studied individual body fluid drug concentrations and integrated 
pharmacokinetic (PK) data with microbiological susceptibility against Mycobacterium 
tuberculosis (MTB). Findings of this thesis support the need to consider dose adjustment in 
TB patients. In order to facilitate dose optimization, we developed supportive analytical tools 
for timely detection of inappropriate drug-exposure. Nevertheless, there are still some 
uncertainties in finding the optimal dose for MFX in individual TB patients. 
 
The role of fluoroquinolones for tuberculosis 
In short, pharmacological treatment success is defined as kill of MTB. However, a sub-
population of slow-replicating TB bacilli is difficult to eradicate. MTB has a complex genetic 
program to escape the impact of host immunity, drugs and hypoxia by switching into this 
latent or persistent phenotype (1). This sub-population is therefore also difficult-to-reach as 
these bacilli persist in the hypoxic regions of pulmonary lesions (2). Because of this drug-
tolerant phenotype, a successful drug-regimen consists of six months of multiple drugs (3), 
including drugs that have efficacy for persister MTB. Few drugs have activity on this 
phenotype; of the first-line drugs, pyrazinamide and especially rifampicin (RIF) have the best 
capacity to reach and kill this MTB population (2,4,5). If RIF cannot be used, because of a 
mutation in the rpoB gene rendering the organism virtually completely unsusceptible for the 
drug, 18-20 months for the traditional multidrug-resistant (MDR)-TB treatment are advised to 
ensure treatment success (6).  
 
The emergence of drug-resistance –with ever increasing inhibitory concentrations for 2nd line 
drugs– is the biggest threat of today’s TB burden (Chapter 1). In Chapter 2A, we have 
reviewed the literature on the PK and pharmacodynamics (PD), as well as on the influence of 
co-administered agents on the PK and PD, of 14 fluoroquinolones (FQs) for drug-resistant 
TB. MFX turned out to be the preferred FQ. Indeed, MFX has high bactericidal and sterilizing 
activity and an excellent penetration in the alveolar macrophages, the epithelial lining fluid 
and the cerebrospinal fluid (7). The later-generation FQs MFX, gatifloxacin (GFX) or 
levofloxacin (LFX) are core agents of the 18-20 month rifampicin-resistant (RR)/MDR-TB 
regimen that is currently recommended, although both MFX and GFX are also in vitro active 
against the non-replicating, anaerobic MTB bacilli (6,8) and therefore capable of shortening 
TB treatment. Also, a stable cure in BALB/c mice after 4 months of an anti-TB backbone of 
MFX and RIF instead of 6 months of isoniazid (INH) and RIF, and the early bactericidal 
activity (EBA) results of MFX and GFX fuelled hope to design a new short-course regimen 
(9-13). This pre-clinical data was the reason to investigate the sterilizing capacity of GFX and 




susceptible (DS)-TB), respectively (14-18). In fact, a 9-12 month regimen based on GFX (or 
MFX) was introduced in the latest (2016) WHO guidelines for RR/MDR-TB, restricted to 
patients with no resistance against FQs and 2nd line injectables, and no previous treatment 
with 2nd line anti-TB agents (6). Given the subject of this thesis, it is important to note that in 
2 cohorts the so-called ‘Bangladesh regimen’ for RR/MDR-TB consisted of a higher than 
standard dosage of GFX (14,16). The two Phase III trials on MFX for pulmonary DS-TB did 
not show the results that were hoped for; after a 4-month MFX-based regimen recurrence 
rates were remarkably higher than after standard 1st line 6-months treatment (17,18). In 
Chapter 2B of this thesis we evaluated the current role of MFX, GFX and LFX for TB, 
including these two key studies, and hypothesized that the TB patients receiving a FQ might 
have been under-dosed based on PK/PD and drug-drug interactions. Ideally, the right fixed 
dose is identified for the majority of patients, and prognostic factors for a low drug-exposure 
are clarified to select the minority of patients that might benefit from plasma drug 
concentration monitoring. In this context, it is important to mention that MFX is still used off-
label for TB and that its potential to prolong QTc remains a concern.  
 
Prognostic markers of a low moxifloxacin exposure 
In Chapter 4A and 4B, we observed a highly variable MFX exposure in our TB patients. We 
have shown that rifampicin drug-drug interaction (RIF DDI), male gender, minimal inhibitory 
concentration (MIC) ≥ 0.25 mg/L, human immunodeficiency virus (HIV)-infection and the 
early phases of TB treatment are potential perpetrators of a too low MFX exposure (19,20). 
With the exception of a high MIC value, each of these markers appears to independently 
change the bioavailability, the volume of distribution and/or the clearance of MFX, potentially 
resulting in a clinically relevant reduction of MFX exposure (7,19,20).  
 
A global intensive concentration-monitoring program could help to further identify prognostic 
markers for a reduced anti-TB drug exposure, for example combinations of anti-TB and 
antiretroviral drugs to avoid in case of HIV co-infection. This program could also help to 
collect repeated concentration measurements in individual patients during the course of anti-
TB drug therapy, thereby testing the hypothesis that TB disease severity influences the PK of 
MFX and other drugs (20). Perhaps, the recently (2017) initiated WHO task force on PK/PD 
of anti-TB drugs would be able to give direction on such a program. In addition, more 
knowledge on the PK mechanism behind prognostic markers might help clinicians to upgrade 
individual treatment regimens. Next to dose optimization, an upgrade might also be switching 
to another drug or temporarily switching to intravenous instead of oral administration. A 
cross-over PK study of oral and intravenous administration of MFX in TB patients, and 
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possibly of other anti-TB drugs, could have added value to investigate gender differences in 
absolute bioavailability (20).           
 
Targets for adequate TB treatment with moxifloxacin  
Data on PK variability of anti-TB drugs is limited, but the problem of low drug-exposure has 
increasingly been recognized. A plasma drug-exposure failing to result in a drug 
concentration providing microbial inhibition is a threat for individual treatment success and 
therefore also, for TB elimination (21,22). However, targets for therapeutic drug monitoring 
(TDM) are generally understudied for anti-TB drugs. In BALB/c mice, the area under the 
concentration-time curve (AUC) divided by the MIC was proven to be the best parameter to 
predict in vivo efficacy of FQs against MTB (23). Apart from the inter-individual variability in 
drug-exposure, there is also a large variability in MICs for TB drugs. A genetic mutation 
results in different phenotypic susceptibility, but also genetic variations among ‘wild type’ 
organisms result in different MIC values (24). Due to occurrence of phenotypic single-drug 
tolerance against metabolically altered sub-populations of slow-replicating MTB bacilli, such 
organisms may survive causing failure or relapse (1). As mentioned earlier, MFX is active in 
vitro against the persisting bacilli in pulmonary or extra-pulmonary lesions, but also in these 
lesions or niches, the drug exposure has to be high enough for anti-microbial killing.   
 
Given as mono-therapy, an AUC0-24h/MIC ratio of ≥100 is suggested for bactericidal activity of 
FQs against MTB. The proposed target was based on the drug-exposure breakpoint 
associated with bactericidal activity of FQs against gram-negative bacteria, and its feasibility 
for bactericidal activity of MFX against MTB was confirmed in an in vitro PD model 
(19,25,26). Also, Monte Carlo simulations (n=10,000) revealed that 59% of the TB patients 
are likely to reach the AUC0-24h/MIC of 100 on 400mg MFX QD (26). In this context, it is 
important to note that this drug-exposure breakpoint was only identified to predict the 







Figure 1. Ion maps of MFX (400mg QD) and of the well-known sterilizing drug pyrazinamide (1500mg 
QD) in lung lesions up to 24 hours post dosage by MALDI mass spectrometry. The white contour lines 
highlight the necrotic centre. The signal intensity is fixed for each drug and indicated by the rainbow 
colour scale bar. Adapted from Prideaux et al. 2015 (2) by permission from Springer Nature.   
 
The penetration of MFX into the lesions tends to depend on the extent of cellularity (Figure 1) 
(2). If MFX is employed to shorten TB treatment, a higher plasma drug-exposure might be 
needed for sufficient drug-levels in more necrotic pulmonary lesions. In these TB patients 
selected for shorter treatment-regimens, a plasma AUC0-24h/MIC of 100 might be too low. As 
mentioned earlier, there also might be a difference in drug-susceptibility between different 
sub-populations of MTB. It could therefore be at least questioned if a dose of 400mg MFX 
QD is high enough to shorten DS-TB treatment to four months only. We therefore propose 
the use of in vitro PD modelling to identify the optimal drug-exposure breakpoint associated 
with sterilizing effect (27). The earlier mentioned global PK data set on anti-TB drugs could 
then contribute to determine clinical dosages for subsets of patients. 
 
Obviously, anti-TB drugs are never given alone, but are part of a multi-drug regimen. PD 
interactions (synergistic, antagonistic or additive) might influence the PD target of MFX. The 
combination of RIF and MFX has a greater suppressive effect on drug-resistant mutant 
selection of MTB in log-phase growth, but a smaller sterilizing effect, compared to the sum of 
the effect of the individual anti-TB drugs (28). For this drug-combination, individual drug-
exposure targets for prevention of drug-resistant mutant selection of log-phase growth bacilli 
are probably lower than in case of mono-therapy (28). A MFX AUC0-24h/MIC of 25 might well 
be optimal for an individual patient with adequate RIF drug-levels. Dose-escalation of MFX 
could still result in failure to result in a sterilizing effect, due to failure to eradicate persister 
organisms. For precise dose adjustment of individual drugs as part of multi-drug regimens, it 
is thus needed to clarify PD interactions and their impact on individual PD targets to be used 
for TDM. Since patients have been reported with MTB resistant against almost all second-
line drugs (29-31), development of new short-course drug-regimens based on drugs with a 
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sterilizing capacity, e.g. RIF or MFX, is needed, but perhaps less potent companion drugs 
could be used as boosters to suppress drug-resistance, if these drugs are used wisely based 
on PK/PD. This perspective is in line with the in vitro synergy between linezolid and the less 
potent drug clarithromycin for TB, and the boosting effect of low-dose ritonavir on exposure 
of a protease-inhibitor in the treatment of HIV (32,33).  
 
Targets for a safe TB treatment with moxifloxacin 
A major concern for prolonged treatment is that adverse effects, like diarrhoea and vomiting, 
may result in a decreased compliance eventually resulting in drug resistance. We reported 
that a daily dose of 400mg MFX was well tolerated in 89 TB patients for a prolonged period, 
but there is also a strong indication that the MFX dose has to be escalated in subsets of 
patients (19,26). A major safety concern for dose-escalation of MFX is its potential to prolong 
the QT interval eventually resulting in a risk of Torsade de Pointes. In healthy volunteers 
(n=20), MFX significantly (p<0.05) increased the QT interval at RR=400-1000ms, compared 
to placebo. In none of the healthy volunteers the QTc interval was >500ms, but a ΔQTc of 
63ms on 400mg MFX QD was observed in one subject, thereby exceeding the commonly 
used threshold for discontinuation of anti-arrhythmic drugs in clinical studies (34,35). In this 
study (34), a strong correlation (r=0.72, p<0.001) was found between the drug-levels in 
plasma and ΔQT interval relative to placebo. We observed a highly variable MFX exposure in 
our TB patients (19,20). However, the median AUC0-24h of 25 mg*h/L on 400mg QD in our TB 
patients is much lower than the geometric mean AUC0-∞ of 42 mg*h/L on 400mg QD in the 
healthy volunteers studied (19,34). Therefore, the QT prolongation risk might be lower in the 
majority of TB patients. Concerning safety of high-dose MFX in TB patients, clinical data is 
limited, but no increase of serious adverse events on 800mg QD has been observed in our 
TB clinic, nor has been published to date (36,37). Recently, a concentration-effect analysis 
based on a thorough QT study was published for Chinese healthy volunteers (n=24) on 
400mg MFX, to investigate, among others, the impact of ethnicity on the relationship of MFX 
concentration with QT interval prolongation (38). Perhaps, such analyses based on published 
MFX PK data of thorough QT studies, for which MFX is used as positive control, could also 
help to test the hypothesis that stepwise dose-optimization in TB patients is safe along with 









Therapeutic drug monitoring for every patient? 
As earlier stated in this thesis, a PK/PD approach could be of added value in finding the best 
fixed FQ dose for the majority of DS- or RR/MDR-TB patients, and to guide the best MFX 
dose in individual TB patients at risk for a too low exposure. The American Thoracic Society 
adopted TDM in their TB treatment guidelines (2016) and the WHO has recently (2017) 
setup a task force on PK/PD of anti-TB drugs. As PK/PD finally gets the attention it deserved, 
PK and PD diagnostics are needed.  
 
In Chapter 3 of this thesis, we developed a LC-MS/MS method to determine MFX in plasma, 
plasma ultra-filtrate and cerebrospinal fluid (39), and in Chapter 5 we have shown that two 
well-timed limited samples, 4 and 14 hours post dose, combined with population PK 
modelling, provide high-quality information on MFX plasma exposure and will overcome the 
need of extensive monitoring (40). However, in TB endemic countries devoid of this PK 
technology, less sophisticated techniques and simple sampling methods are needed to be 
able to quickly stepwise adjust to an effective and safe dose. We therefore also developed a 
Thin Layer Chromatography (TLC) method, using non-invasive oral fluid sampling (Chapter 
6). To the best of our knowledge, this semi-quantitative method was the first technically 
validated. This technical validation is essential as the inter-observer error in visual read-out 
may be a potential flaw with major impact on clinical decision-making. Our observations 
provide evidence to support personalized dosing, but this low-tech test has to be evaluated in 
a larger sample of patients (41). Return of investment may be high as inadequately treated 
patients feed the TB epidemic. International organisations, like the Foundation for Innovative 
New Diagnostics (FIND), are needed for creation of awareness, on-site implementation and 
on-site evaluation of rapid TDM diagnostics for key anti-TB drugs, analogous to rapid 
diagnostics to detect drug-resistance against the same drugs. The number of samples 
needed for TDM could be limited and the sampling time-points could be optimized by 
developing more (practically applicable) limited sampling strategies for specific patient 
groups based on a larger population PK data set.  
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In conclusion, if the PK variability of MFX is confirmed in a preferably larger PK data set, this 
could have several clinical implications. Further selection of patients at risk for a too low 
drug-exposure should be needed to safeguard the use of this key anti-TB drug. Standard 
dosages should be identified for subsets of patients based on established PK/PD targets. 
TDM diagnostics for individual dose titration in patients at risk for a too low drug-exposure 
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